GlaxoSmithKline plc (the 'Company')
Transaction notification
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Sir Andrew Witty
b)
Position/status
CEO
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
GlaxoSmithKline plc
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 14 July 2016 on Ordinary Shares held in the Company's 2009 Performance Share Plan.
Price(s) and volume(s)
Price(s)
Volume(s)
£16.285
3.975
217.131
580.125
1,329.326
3,988.006
5,452.053
5,905.210
d)
Aggregated information
Aggregated volume Price
17,475.826
e)
Date of the transaction
2016-07-14
f)
Place of the transaction
n/a